Literature DB >> 27798878

Expression of Maternal Embryonic Leucine Zipper Kinase (MELK) Correlates to Malignant Potentials in Hepatocellular Carcinoma.

Kiyokazu Hiwatashi1, Shinichi Ueno2, Masahiko Sakoda1, Satoshi Iino1, Koji Minami1, Keiichi Yonemori1, Yuka Nishizono1, Hiroshi Kurahara1, Yuko Mataki1, Kosei Maemura1, Hiroyuki Shinchi3, Shoji Natsugoe1.   

Abstract

BACKGROUND/AIM: Maternal embryonic leucine zipper kinase (MELK) is categorized as a member of AMP-activated protein kinase families. Various MELK-associated cellular and biological processes affect multiple stages of tumorigenesis. The aim of the present study was to clarify the relationship between MELK expression and hepatocellular carcinoma (HCC) clinicopathological features.
MATERIALS AND METHODS: In thirty conserved frozen primary HCC and non-HCC samples MELK mRNA expression was examined by quantitative real-time polymerase chain reaction (PCR).
RESULTS: HCC tissues exhibited significantly higher expression levels compared to non-cancerous tissues. MELK expression had a statistically parallel correlation between tumor diameter and protein induced by vitamin K absence or antagonist II (PIVKA-II). The overall survival (OS) and recurrence-free survival (RFS) of the low MELK mRNA expression group was significantly longer than that of the high MELK mRNA expression group.
CONCLUSION: MELK expression in HCC is extremely intense compared to its expression reported in other types of cancer. MELK could be a promising effective tumor marker of HCC and further consideration is needed. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  HCC; MELK; PCR; tumor marker

Mesh:

Substances:

Year:  2016        PMID: 27798878     DOI: 10.21873/anticanres.11088

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03

2.  Identification of potential hub genes associated with the pathogenesis and prognosis of hepatocellular carcinoma via integrated bioinformatics analysis.

Authors:  Ziqi Meng; Jiarui Wu; Xinkui Liu; Wei Zhou; Mengwei Ni; Shuyu Liu; Siyu Guo; Shanshan Jia; Jingyuan Zhang
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

3.  Identification of Key Genes and Pathways in Pancreatic Cancer Gene Expression Profile by Integrative Analysis.

Authors:  Wenzong Lu; Ning Li; Fuyuan Liao
Journal:  Genes (Basel)       Date:  2019-08-13       Impact factor: 4.096

4.  Identifying potential prognosis markers in hepatocellular carcinoma via integrated bioinformatics analysis and biological experiments.

Authors:  Xueting Hu; Jian Zhou; Yan Zhang; Yindi Zeng; Guitao Jie; Sheng Wang; Aixiang Yang; Menghui Zhang
Journal:  Front Genet       Date:  2022-07-19       Impact factor: 4.772

5.  Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer.

Authors:  Xi Sun; Shuning Ding; Shuangshuang Lu; Zheng Wang; Xiaosong Chen; Kunwei Shen
Journal:  Onco Targets Ther       Date:  2021-06-04       Impact factor: 4.147

6.  Up-Regulated Maternal Embryonic Leucine Zipper Kinase Predicts Poor Prognosis of Hepatocellular Carcinoma Patients in a Chinese Han Population.

Authors:  Shaohan Wu; Xujian Chen; Chundong Hu; Jing Wang; Yiyu Shen; Zhengxiang Zhong
Journal:  Med Sci Monit       Date:  2017-12-01

7.  Challenges in validating candidate therapeutic targets in cancer.

Authors:  Jeffrey Settleman; Charles L Sawyers; Tony Hunter
Journal:  Elife       Date:  2018-02-08       Impact factor: 8.140

8.  Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target in lung adenocarcinoma.

Authors:  Shengsong Chen; Zhanpeng Lu; Xiaoyong Chen; Xiya Wu; Hongying Tu; Lingling Yu; Zuke Xiao
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

9.  Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.

Authors:  Antonio Cigliano; Maria Giulia Pilo; Marta Mela; Silvia Ribback; Frank Dombrowski; Giovanni Mario Pes; Antonio Cossu; Matthias Evert; Diego Francesco Calvisi; Kirsten Utpatel
Journal:  Medicina (Kaunas)       Date:  2019-12-18       Impact factor: 2.430

10.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.